How Analysts Changed Views on BioMarin After Earnings

Health and Healthcare

Published: February 28, 2016 10:45 am

Last Updated: January 13, 2020 12:36 pm

BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN) reported its fourth-quarter financial results after the markets closed Thursday. Investors really took to this stock and there was a favorable jump after the report. However, analysts took a slightly different perspective and cut their price targets.

The company said it had $0.40 in earnings per share (EPS) on $227.9 million in revenue, which compared to consensus estimates from Thomson Reuters of $0.99 in EPS on revenue of $224.38 million. The same period from last year had a net loss of $0.47 per share on $230.85 million in revenue.

In terms of guidance for 2016, the company expects to have a non-GAP net loss of in the range of $75 million to $100 million, as well as total revenues in the range of $1.05 billion to $1.10 million. The consensus estimates for the full year call for a net loss of $2.27 per share on $1.15 billion in revenue.

A few analysts weighed in on BioMarin after earnings:

JPMorgan has an Overweight rating and lowered its price target to $117 from $121.
Piper Jaffray has an Overweight rating and lowered its price target to $107 from $118.
Jefferies has a Buy rating and lowered its price target from $132 to $120.
RBC has an Outperform rating and lowered its price target to $125 from $155.
Goldman Sachs lowered its price target to $129 from $131.